Clearsight's deep industry relationships, dedication to our transaction and resolve to keep our best interests at center made them invaluable to our process and our founding partner group."Ĭlearsight Co-Founder and Managing Director Joel Kallett noted, "We first had the pleasure of advising the ClearView team in their recapitalization by RLH Equity Partners back in 2017. When it came time to consider the next step for ClearView, there was no question we would retain Clearsight again as our investment banking partner. Richard Mynahan, Partner at ClearView, applauded the deal closure, "Over the years, we have come to know Clearsight as a trusted and knowledgeable advisor to our firm. The investment will also allow ClearView to provide a wider array of pricing & market access and data analytics solutions to their existing client base, while facilitating additional relationships in the sector. GHO Capital's investment will enhance ClearView's market-leading status by accelerating the Company's expansion into international markets, particularly those in Europe. The Company's project-based engagements include supporting pharmaceutical drug sponsors through the R&D and commercialization process and aiding clinical and commercial portfolio development. ClearView provides valuable expertise and actionable insights to a wide range of market sub-sectors including Big Pharma/Biopharma, Diagnostics, MedTech and Life Sciences services/tools segments. Founded in Boston in 2007, the Company has since expanded to a team of ~300 professionals across New York, San Francisco, London and Zurich. This transaction underscores Clearsight as the preeminent advisor to strategy consulting firms serving the life sciences and healthcare sectors.ĬlearView is the leading independent strategy consulting firm exclusively focused on the life sciences industry. Clearsight served as a strategic investment banking advisor to ClearView Healthcare Partners, LLC ("ClearView" or the "Company") in its recapitalization by GHO Capital Partners, LLP ("GHO Capital").
("Clearsight") is pleased to announce another successful transaction in its Life Sciences Consulting practice. 1, 2021 /PRNewswire/ - Clearsight Advisors, Inc. We congratulate the Company’s founders – Rich Mynahan, Steve Chao, and Kevin Richard – and the entire ClearView organization on their achievements and wish the Company continued success in the future.Ĭlearsight Advisors and Houlihan Lokey acted as strategic co-advisors to ClearView Winston & Strawn and Foley Hoag LLP acted as legal advisors and RSM US LLP served as financial and tax advisor to the Company.MCLEAN, Va., Sept. Most notably, ClearView was included in Vault’s prestigious annual Top 50 Consulting Firms and Best Boutique Firms lists every year during RLH’s engagement with the Company and earned #1 Best Boutique honors in 2020. RLH is very proud of Clearview’s success in growing its revenue three-fold organically during RLH’s involvement while concurrently earning numerous recognitions of the strength of its culture. The Company’s clients encompass a wide range of enterprises throughout the Big Pharma, Biopharma, Diagnostics, and MedTech sectors.ĬlearView is able to deliver a distinctive combination of deep and diversified therapeutic expertise together with business insights because of the Company’s ability to attract and retain exceptional talent. ClearView, the leading independent strategy consulting firm focused on the life sciences, provides high-value guidance to its clients in connection with (i) key decision points in the development and commercialization process and (ii) the management of growth and innovation across clients’ entire clinical and commercial portfolios. RLH Equity Partners is pleased to announce that GHO Capital Partners LLP, a European specialist investor in global healthcare, has acquired a majority ownership position in RLH’s portfolio company, ClearView Healthcare Partners (“ClearView” or “Company”) from RLH and ClearView management.
0 kommentar(er)
